Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. by Hanna, Ramy M et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
1-1-2020 
Refractory scleroderma renal crisis precipitated after high-dose 
oral corticosteroids and concurrent intravitreal injection of 
bevacizumab. 
Ramy M Hanna 
Lama Abdelnour 
Jonathan E Zuckerman 
Antoney J Ferrey 
Alex Pai 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Nephrology Commons, and the Pathology Commons 
Recommended Citation 
Hanna, Ramy M; Abdelnour, Lama; Zuckerman, Jonathan E; Ferrey, Antoney J; Pai, Alex; Vahabzadeh, 
Kambiz; Wilson, James; Torres, Everado A; Kalantar-Zadeh, Kamyar; and Kurtz, Ira B, "Refractory 
scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal 
injection of bevacizumab." (2020). Articles, Abstracts, and Reports. 3661. 
https://digitalcommons.psjhealth.org/publications/3661 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Ramy M Hanna, Lama Abdelnour, Jonathan E Zuckerman, Antoney J Ferrey, Alex Pai, Kambiz Vahabzadeh, 
James Wilson, Everado A Torres, Kamyar Kalantar-Zadeh, and Ira B Kurtz 
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/3661 
https://doi.org/10.1177/2050313X20952650
SAGE Open Medical Case Reports
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and 
distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages 
(https://us.sagepub.com/en-us/nam/open-access-at-sage).
SAGE Open Medical Case Reports
Volume 8: 1 –7
© The Author(s) 2020
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1 77/205 31 X209526
journals.sagepub.com/home/sco
Introduction
Thrombotic microangiopathy (TMA) has been noted to 
develop in many disease states that have both inflammation 
and endothelial injury.1 There are many complex pathways 
involved; however, it has become clear that endothelial 
injury can occur more easily in certain genetically suscepti-
ble individuals.2 It has also been observed that if endothelial 
damage and complement activation are sufficiently severe, 
TMA can occur despite the appearance of an apparently 
benign genetic environment.3 Scleroderma renal crisis (SRC) 
usually presents with a TMA that occurs within the context 
of malignant hypertension (MHT) and progressive renal 
dysfunction.4
It is important to note that MHT is not always observed, 
and renal-limited TMAs related to SRC have been reported 
in individuals without findings of hypertension.5–7 The rela-
tionship between complement activation, rheumatologic 
syndromes, and endothelial dysfunction plays a key role in 
patients with MHT, SRC, and TMA. Timmermans et al.8 
recently reported the association between some genetic 
abnormalities to chronic hypertension with renal-limited 
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Abstract
Scleroderma renal crisis is a serious complication that can develop in certain patients with systemic sclerosis. Some risks 
have been identified as potential triggers of scleroderma renal crisis, including the high-dose oral corticosteroids. Here, we 
present a patient who developed clinically severe systemic sclerosis and scleroderma renal crisis after exposure to oral 
corticosteroids and intravitreal vascular endothelial growth factor blockade with bevacizumab for cotton wool spots. The 
patient’s scleroderma renal crisis was severe, progressive, and refractory to the standard of care therapy: oral captopril. 
Biopsy showed a diffuse thrombotic microangiopathy and findings consistent with scleroderma renal crisis. We hypothesize 
that depletion of systemic vascular endothelial growth factor with intravitreal anti–vascular endothelial growth factor 
injections likely contributed to the particularly severe presentation seen in this case. Though the finding of a monoclonal 
gammopathy of undetermined significance is another complicating factor, this case suggests that vascular endothelial growth 
factor inhibition may be a newly recognized trigger of scleroderma renal crisis.
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TMA. Figure 1 explains the association between comple-
ment activation, genetic complement dysfunction, and 
endothelial shear stress that can create the conditions for a 
TMA to develop.
The use of high-dose corticosteroids is known to increase 
the risk of SRC, thus explaining why steroid therapy has 
fallen out of favor as a treatment of systemic sclerosis (Ssc).9 
The current treatment for SRC consists of renin angiotensin 
aldosterone system (RAAS) blockade and low dose aspirin 
for anti-platelet effect.10,11 The clinical benefit does not seem 
to be uniform, and there are no proven second- or third-line 
treatment options.12 Experimental therapy with anti-endothe-
lin agents, plasmapheresis, and complement blockade has 
been described for SRC.13
Another agent recently noted to be systemically absorbed 
and proven to disrupt systemic vascular endothelial growth 
factor (VEGF) levels are intravitreal injections of VEGF 
inhibiting monoclonal antibodies.14–16 We present a case of 
SRC that initially developed after the patient was exposed to 
corticosteroids. He was subsequently exposed to intravitreal 
VEGF blockade and had rapidly progressive hypertension 
with subacute kidney injury refractory to the standard of care 
therapy. We thus bring attention to a possible role for VEGF 
blockade in accelerating SRC in this patient who received 
intravitreal injections of bevacizumab.
Case report
A 37-year-old male developed a sudden progressive onset of 
worsening skin thickening, initially localized to his torso but 
had since begun to spread. There was no cyanotic discoloration 
of extremities that would suggest Raynaud’s phenomenon. The 
patient also noted progressive weight loss up to 20–30 pounds 
(lbs) over the first 3 months of his initial presentation. The 
patient described fatigue, but without wheezing or dyspnea.
His systolic blood pressure was initially 100–110 mmHg, 
and he had no previous history of hypertension. His renal 
function was within normal range, with a serum creatinine of 
0.8 mg/dL. Notably, he had a history of hepatitis B, treated 
with entecavir, without evidence of active disease (precluded 
use of B cell depletion therapy). His serological testing 
revealed a negative anti-nuclear antibody (titer of 0), nega-
tive anti-Smith antibodies, and negative anti-ribonucleopro-
tein. Anti-Scl-70 (anti-topoisomerase I antibody) levels were 
detected at a low level, but within the reference range (3–
4 AU/mL). The triple negative profile was unusual, and as 
such more investigation was warranted before considering a 
diagnosis of Ssc.
A skin biopsy was sought from the patient’s left upper 
extremity at a site of severe skin thickening. The area of skin 
thickening was representative of changes over much of the 
patient’s skin surface, his modified Rodnan skin score was 
31, and nail bed capillaroscopy exam was positive and sug-
gestive of Ssc. There was no evidence of pericardial friction 
rub noted on exam, and echocardiography did not reveal pul-
monary hypertension or a pericardial effusion.
The skin biopsy sample was read by the pathologist as 
suspicious for morphea versus scleroderma/Ssc. His renal 
function was normal until that time, and he had no gadolin-
ium exposure. We clarified the point about gadolinium expo-
sure to ensure that the patient did not have nephrogenic 
systemic fibrosis (NSF). The diagnosis of Ssc was more rig-
orously suspected on the basis of the skin biopsy results and 
careful clinical exam that revealed diffuse skin thickening 
and sclerodactyly. He was subsequently started on mycophe-
nolate mofetil for treatment of Ssc.
A curious feature of his presentation was the finding of an 
IgG lambda monoclonal light chain of undetermined signifi-
cance at 1.1 g/dL. A bone marrow biopsy was obtained and 
showed a normal cellular marrow, of which 10% were 
lambda restricted plasma cells, confirmed by flow cytome-
try. Cytogenetics/fluorescent in situ hybridization demon-
strated a gain of 1q, gain of 5q, monosomy 13, and 14q 
minus ranging from 67% to 94%, karyotype was 46, XY.
Given the complexity of this case, he saw multiple provid-
ers at various health care centers. He was started on high-dose 
oral corticosteroids (60 mg), the reason for starting this agent 
was not immediately apparent to our team. Subsequently, he 
had a rise in blood pressure and serum creatinine from 0.8 to 
1.1 mg/dL. This occurred abruptly after starting the pred-
nisone, 3 months after his initial presentation. The patient’s 
blood pressure rose from 120–130 mmHg systolic baseline to 
140–150 mmHg during this time.
He developed blurry vision and was referred to ophthal-
mology where dilated eye exam revealed “cotton wool 
Figure 1. Schematic of causal theories of hypertension and 
thrombotic microangiopathy.
Black arrows explain standard theory that hypertension causes endothelial 
injury and complement activation. Red arrows show alternative theory, 
favored by pathological review that thrombotic microangiopathy resulting 
from genetic causes triggers hypertension and results in chronic irreversible 
vascular injury. Complement blockade maybe efficacious if it blocks chronic 
vascular injury, but development of vascular injury presages irreversible 
renal dysfunction.
CM: complement mediated; HTN: hypertension; TMA: thrombotic 
microangiopathy.
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spots.” He was given 1.25 mg intravitreally injected bevaci-
zumab on two occasions. A week later, an even sharper rise 
in blood pressure was noted and accompanied by worsening 
serum Cr to 1.4 mg/dL. Figure 2 shows the trends of serum 
creatinine, systolic blood pressure, and diastolic blood pres-
sures for this case. The data are presented in months after 
presentation to preserve anonymity.
He was admitted a week later with severe hypertension 
with systolic blood pressures of 200–220 mmHg. A marked 
increase in proteinuria from undetectable to a urine protein 
to creatinine ratio of 1-gram protein per gram creatinine was 
noted during this admission. A renal ultrasound and Doppler 
evaluation revealed normal sized kidneys without any evi-
dence of atrophy or size mismatch, along with no evidence 
of renal artery stenosis. Given the sudden change in blood 
pressure, renal function, proteinuria, and recent exposure to 
oral corticosteroids, SRC was suspected. A complement-
mediated TMA related to intravitreal VEGF inhibition could 
also not be ruled out. As such, a renal biopsy was obtained 
after his blood pressure was controlled to look for these diag-
nostic possibilities.
The patient’s renal biopsy (Figure 3) contained 57 glomer-
uli (1 globally sclerotic) and light microscopy demonstrated 
arteries with near-complete luminal occlusion by fibrointimal 
proliferation and adjacent ischemic tubulopathy. Mucoid inti-
mal hyperplasia was noted in several arteries as well on tri-
chrome stain, along with “onion skin” changes and bloodless 
glomeruli. Some rare glomeruli exhibit segmental small 
luminal thromboses. There was diffuse but early/evolving 
tubular atrophy as well as early interstitial fibrosis associated 
with the ischemic tubulopathy. Immunofluorescence was 
negative for any immune complex staining.
A Congo-red stain was negative for amyloid deposition. 
Electron microscopic studies demonstrated marked ischemic-
type corrugation of glomerular capillary loops as well as exten-
sive endothelial cell swelling often with near-complete luminal 
occlusion. Glomerular subendothelial spaces were widened 
and showed occasional neomembrane formation. Luminal 
platelet aggregates were present. No electron dense, organized, 
or crystalline deposits were present in any compartment. The 
overall diagnosis was a diffuse TMA with arterial predomi-
nance, consistent with Ssc-associated renal disease.
The patient’s lactate dehydrogenase showed a low-level 
elevation at 344 IU/L, which is near the upper limit of nor-
mal. A disintegrin and metalloproteinase level motif #1, 
member 13 (ADAMTS13) level was 75%, ruling out 
ADAMTS13 deficiency and thrombotic thrombocytopenic 
purpura (TTP). International normalized ratio was normal 
at 1 with a normal prothrombin time of 10.5 s, and a nor-
mal activated partial thromboplastin time at 28 s. Platelets 
were normal ranging 300,000–358,000/µL, hemoglobin 
was 11.8 g/dL, and there was no evidence of microangio-
pathic hemolysis. Schistocytes were not noted during the 
patient’s course at any time. Reticulocytes were normal at 
1.3%, iron saturation was 43%, and vitamin B12 level was 
451 pg/mL. Shigatoxin was negative in the patient’s stool 
specimen. The data support a renal-limited TMA without 
peripheral hemolysis.
Figure 2. Serum creatinine (mg/dL) versus months after presentation with SRC.
BP: blood pressure; mg/dL: milligrams/deciliter; DBP: diastolic blood pressure; H: hospitalization for renal crisis; mmHg: millimeters of mercury; RBx: 
renal biopsy; SBP: systolic blood pressure; SBx: skin biopsy; sCr: serum creatinine; SRC: scleroderma renal crisis. Black arrow: corticosteroids 1 mg/kg; 
Red arrow: bevacizumab 1.25 mg injections × 2; Green arrow: renal replacement therapy—hemodialysis.
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Serum VEGF level obtained weeks after injection with 
bevacizumab was 52 pg/mL. This level is near to lower limit 
of normal, and could suggest some level of VEGF depletion. 
The lack of an elevated level also rules out POEMS (poly-
neuropathy, organomegaly, endocrinopathy, M-protein, and 
skin changes) syndrome which was in differential diagnosis, 
and is characterized by a high serum VEGF level.
Complement genetics were obtained and demonstrated a 
heterozygous, missense variant (c.1058C>T) of membrane 
cofactor protein (MCP) (alanine 353 to valine 353 substitu-
tion). This was previously associated with atypical hemo-
lytic uremic syndrome (aHUS) presented in the case series of 
Fang et al.17 in 2008. The risks and benefits of complement 
blockade were explained to patient, who was started on low 
dose 81-mg aspirin and captopril titration as inpatient and 
outpatient as the standard of care. The patient was made 
aware of the favorable response of eculizumab in 66.7% of 
SRC cases.18–24
The patient ultimately declined use of complement block-
ade despite the copious explanation of benefits, given the 
risks reported for meningitis despite existence of vaccines 
and prophylactic antibiotics. The patient’s renal function con-
tinued to worsen with serum creatinine rising to 1.9 mg/dL, to 
2.7 mg/dL, and then to 7 mg/dL over the course of 5 months. 
Currently, he is receiving plasmapheresis to improve renal 
function, and renal replacement therapy. The plan is to pursue 
renal transplantation with complement blockade with a C5 or 
C3 blocking agent, depending on availability, and the patient’s 
willingness to try this adjunct therapy.
Discussion
Ssc-induced renal disease covers a wide spectrum, from a 
chronic interstitial nephritis with resulting mild proteinuria 
and indolent renal dysfunction, to the more severe complica-
tion of SRC.12 The presentation of renal crisis includes 
severe hypertension with findings of end organ dysfunction 
with the risk of irreversible renal failure.4 The pathological 
findings of SRC are generally an arterial/arteriolar predomi-
nant TMA often with marked subendothelial edema and 
fibrointimal proliferation resulting in prominent onion skin-
ning–type change with or without concurrent glomerular 
thrombosis.4
This particular patient’s presentation is unique in that a 
week before the patient was hospitalized with MHT, he 
received intravitreal VEGF injections for cotton wool spots 
in the eye by ophthalmology. There are now increasing 
reports of intravitreal injections resulting in VEGF deple-
tion and glomerular disease including TMA, collapsing 
focal and segmental sclerosis (FSGS), as well as other 
causes of nephrotic syndrome.14–16,25–27 The renal biopsy 
findings we presented could be compatible with TMA from 
VEGF depletion and from SRC. Given the presence of Ssc 
clinically predating the intravitreal VEGF inhibition injec-
tions, it was surmised that the patient’s Ssc was likely exac-
erbated by VEGF blockade and hypertension as well as the 
oral corticosteroids.
Given the refractory nature of the TMA, the evidence for 
eculizumab was reviewed with the patient, but he felt that the 
risk of meningitis outweighed the potential benefit. In all, 
nine patients with Ssc syndromes were treated with eculi-
zumab, with six patients showing a positive response. Table 1 
details the cases of SRC treated with eculizumab and the cor-
responding clinical response data.18–24
In addition, this patient’s genetic testing led to some 
equivocal findings of alleles not generally thought to be path-
ogenic. We cannot exclude a yet undescribed role for these 
genetic variants which affect susceptibility to complement 
Figure 3. Features of active thrombotic microangiopathy on renal biopsy: (a) arteries with near-complete luminal occlusion by 
fibrointimal proliferation (arrows) and adjacent ischemic tubulopathy (periodic acid Schiff stain, 100×); (b) artery with mucoid intimal 
hyperplasia (arrow) (trichrome stain 200×); (c) artery with “onion skin” change (trichrome stain 400×); and (d) “bloodless” glomerulus 
(H&E stain, 400×).
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amplifying and endothelium disruptive insults. It is probable 
that genetic susceptibility and trigger strength should both be 
taken into account when TMA episodes are observed. A “slid-
ing scale” of genetic risk and trigger strength are likely oper-
ating concurrently,28 with more purely genetic presentations 
resulting from minor environmental triggering exposures and 
more acquired presentations occurring from severe triggers.1 
See Figure 4 for a diagram illustrating this concept in TMA 
susceptibility.
The patient’s monoclonal gammopathy also adds com-
plexity to this case. TMA is considered to fall within the 
monoclonal gammopathy of renal significance (MGRS) 
spectrum of lesions.29 Furthermore, paraneoplastic sclero-
derma like-tissue reactions have been reported.30 The degree 
to which the patient’s underlying plasma cell dyscrasia may 
have influenced this patient’s clinical course are uncertain. 
The renal biopsy did not show any evidence for any other 
MGRS-associated lesion such as amyloidosis, light chain 
proximal tubulopathy, light chain cast nephropathy, light 
chain deposition disease, FSGS, or heavy chain deposition 
disease.31,32
Conclusion
We report a 37-year old male w/severe Ssc and the onset of 
SRC after oral corticosteroid treatment, and intravitreal VEGF 
blockade. More work remains to be done regarding the rela-
tionship of VEGF signaling and SRC. The effects of alterna-
tive complement pathway and VEGF blockade remain 
interesting due to the association of SRC with TMA. Oral cor-
ticosteroids should be avoided in Ssc, and we believe caution 
should be used when prescribing intravitreal VEGF blockade 
in patients with Ssc. Treatment with complement blockade 
needs to be thoroughly studied due to pathophysiological 
overlap between SRC and complement-mediated TMA.
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Table 1. Cases of eculizumab therapy in patients with TMA due to SRC.
Reference # Eculizumab 
treated
Age Gender Renal recovery ESRD Death
[18] 2 56, 63 M, M 50%, 1 with CKD 50% 0%
[19] 1 28 F 0% 100% 100%
[20] 1 62 M 100% 0% 0%
[21] 1 56 M 100% 0% 0%
[22] 1 46 F 100% 0% 0%
[23] 1 40 F 100% 0% 0%
[24] 2 28, 48 F, F 50% 50% 50%
CKD: chronic kidney disease; ESRD: end stage renal disease; F: female; M: male.
Figure 4. The interplay between genetic risk and trigger strength in triggering thrombotic microangiopathy.
aHUS: atypical hemolytic uremic syndrome; Amp: amplification; Comp: complement; TMA: thrombotic microangiopathy.
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